Evidence map›Paper›PMID 32258060›Full record

ReviewFrontiers in cardiovascular medicine2020

Cardiotoxicity of Anthracyclines.

Daniela Cardinale, Fabiani Iacopo, Carlo Maria Cipolla

4 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cardiovascular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 267 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
267citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05595109 phase2 / phase3unknown statusnot on this mapstarted 2022, after this paper: background citation

The Possible Protective Role of Silymarin Against Chemotherapy Induced Toxicities and Cognitive Impairment in Breast Cancer Patients

TypeinterventionalSponsorTanta UniversityRan2022 to 2024Enrolled56ConditionsBreast Cancer, Peripheral Neuropathy, Cardiac Toxicities, Hepatic ToxicityArmsSilymarin, Placebo
NCT05882578 nacompletednot on this mapstarted 2023, after this paper: background citation

Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals

TypeinterventionalSponsorTigers Running ClubRan2023 to 2023Enrolled74ConditionsBreast Cancer, Cancer SurvivorsArmsOncological physical exercise intervention, Active Physical Activities intervention
NCT06005259 phase4unknown statusnot on this mapstarted 2023, after this paper: background citation

Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity: a Randomized Clinical Trial (SPIROTOX Trial)

TypeinterventionalSponsorUniversity of Sao PauloRan2023 to 2025Enrolled264ConditionsCardiotoxicity, Neoplasms, Chemotherapy Effect, Heart FailureArmsSpironolactone, Placebo
NCT06155331 phase2completednot on this mapstarted 2023, after this paper: background citation

Clinical Study to Evaluate the Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

TypeinterventionalSponsorTanta UniversityRan2023 to 2025Enrolled44ConditionsBreast Cancer Stage 2 and 3ArmsFenofibrate, Placebo, Doxorubicin, Cyclophosphamide
3 · Its place in the literature

Who cites it

267 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

207 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Daniela CardinaleCardioncology Unit, European Institute of Oncology, IRCCS, Milan, Italy.
Fabiani IacopoCardioncology Unit, European Institute of Oncology, IRCCS, Milan, Italy.
Carlo Maria CipollaCardiology Division, European Institute of Oncology, IRCCS, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiotoxicity is a feared side effect that may limit the clinical use of anthracyclines. It may indeed affect the quality of life and survival of patients with cancer, regardless of oncological prognosis. This paper provides an overview of anthracycline-induced cardiotoxicity in terms of definition, classification, incidence, risk factors, possible mechanisms, diagnosis, and treatment. We also report effective strategies for preventing cardiotoxicity. In addition, we discuss limiting current approaches, the need for a new classification, and early cardiotoxicity detection and treatment. Probably, anthracycline-induced cardiotoxicity is a continuous phenomenon that starts from myocardial cell injury; it is followed by left ventricular ejection fraction (LVEF) and, if not diagnosed and cured early, progressively leads to symptomatic heart failure. Anthracycline-induced cardiotoxicity can be detected at a preclinical phase. The role of biomarkers, in particular troponins, in identifying subclinical cardiotoxicity and its therapy with angiotensin-converting enzyme inhibitors (mainly enalapril) to prevent LVEF reduction is a recognized and effective strategy. If cardiac dysfunction has already occurred, partial or complete LVEF recovery may still be obtained in case of early detection of cardiotoxicity and prompt heart failure treatment.

Indexed as

ACE-inhibitorsanthracyclinesbeta-blockerscardiotoxicityearly detectionpreventionreversibilitytroponin

Identifiers

PMID32258060
PMCPMC7093379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.